DBC 1 Antibody (YA5182)

Cat. No.: HY-P85490: Data Sheet User Guide for Antibodies
FAQs
Technical Support

DBC 1 Antibody (YA5182) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to DBC 1.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

DBC 1 Antibody (YA5182) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to DBC 1.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Observed band size: 130 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse, Rat, Monkey

SwissProt ID

Q8N163

Gene ID

57805 [NCBI]

Immunogen

Purified recombinant human DBC1 protein fragments expressed in E.coli

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:200

Purity	affinity chromatography.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions (PubMed:22446626). Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis (PubMed:18235501, PubMed:18235502, PubMed:23352644). Inhibits SUV39H1 methyltransferase activity (PubMed:19218236). Mediates ligand-dependent transcriptional activation by nuclear hormone receptors (PubMed:19131338). Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress (PubMed:23398316). Regulates the circadian expression of the core clock components NR1D1 and BMAL1 (PubMed:23398316). Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978)

Subcellular Localization：Nucleus; Cytoplasm; Cytoplasm, cytoskeleton, spindle

Expression：
Tissue_specificity:It is expressed in gastric cancer tissues, and its expression level gradually increases with the progression of cancer (protein level) . It is widely expressed in normal tissues. It is expressed in 84% to 100% of breast cancer, lung cancer, and colon cancer tumor tissues.

Isoforms & Post-Translational Modification：Q8N163 has 2 isomers: Q8N163-1: 102902 Da (predicted); Q8N163-2: 103143 Da (predicted).
ATM/ATR-mediated phosphorylation at Thr-454 upon DNA damage promotes binding to SIRT1. Phosphorylation at Thr-454 promotes its sumoylation by switching the binding partner of CCAR2 from SENP1 to PIAS3;Acetylation at Lys-112 and Lys-215 by KAT8 prevents inhibitory binding to SIRT1 and increases its deacetylase activity;Genotoxic stress induces its sumoylation and sumoylation promotes the SIRT1-CCAR2 interaction which in turn inhibits SIRT1-mediated deacetylation of p53/TP53. Sumoylation leads to transcriptional activation of p53/TP53 by sequestering SIRT1 from p53/TP53. Desumoylated by SENP1

Subunit：Component of the DBIRD complex (PubMed:22446626). Interacts with ZNF326/ZIRD; the interaction is direct (PubMed:22446626).

Synonyms

DBCCR1; Deleted in bladder cancer protein 1; Deleted in bladder cancer protein 1 recursor; FAM5A; Protein FAM5A.

Documentation

User Guide for Antibodies (1077 KB)